These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39110200)

  • 21. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
    Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
    PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Applied genomics in MPN presentation.
    Moliterno AR; Kaizer H
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):434-439. PubMed ID: 33275725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
    Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
    Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular Pathogenesis of Myeloproliferative Neoplasms.
    Rolles B; Mullally A
    Curr Hematol Malig Rep; 2022 Dec; 17(6):319-329. PubMed ID: 36336766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature.
    Goulart H; Masarova L; Mesa R; Harrison C; Kiladjian JJ; Pemmaraju N
    Br J Haematol; 2024 Jul; 205(1):48-60. PubMed ID: 38853641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
    Helbig G
    Med Oncol; 2018 Aug; 35(9):119. PubMed ID: 30074114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study.
    England JT; Szuber N; Sirhan S; Dunne T; Cerquozzi S; Hill M; Villeneuve PJA; Ho JM; Sadikovic B; Bhai P; Krishnan N; Dowhanik S; Hillis C; Capo-Chichi JM; Tsui H; Cheung V; Gauthier K; Sibai H; Davidson MB; Bankar A; Kotchetkov R; Gupta V; Maze D
    Leukemia; 2024 Mar; 38(3):570-578. PubMed ID: 38321107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
    Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in
    Wang Y; Ran F; Lin J; Zhang J; Ma D
    Technol Cancer Res Treat; 2023; 22():15330338231154092. PubMed ID: 36744404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report.
    He Z; Wang B; Chen L; Huang Y; Wang H; Yang M; Xiao X; Lu Y; Chen J; Wu Y
    Medicine (Baltimore); 2018 Nov; 97(46):e13220. PubMed ID: 30431598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms.
    Grinsztejn E; Percy MJ; McClenaghan D; Quintana M; Cuthbert RJ; McMullin MF
    Int J Lab Hematol; 2016 Feb; 38(1):102-6. PubMed ID: 26555437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
    Rampal R; Ahn J; Abdel-Wahab O; Nahas M; Wang K; Lipson D; Otto GA; Yelensky R; Hricik T; McKenney AS; Chiosis G; Chung YR; Pandey S; van den Brink MR; Armstrong SA; Dogan A; Intlekofer A; Manshouri T; Park CY; Verstovsek S; Rapaport F; Stephens PJ; Miller VA; Levine RL
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5401-10. PubMed ID: 25516983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Philadelphia-negative myeloproliferative neoplasms among Kuwaiti Nationals.
    Alshemmari S; Almazyad M; Alwehaib A; Ameen R
    Cancer Med; 2021 Jan; 10(1):365-371. PubMed ID: 33280271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The characteristics of
    Najim M; Abu-Tineh M; Alshurafa A; Ibrahim MIM; Ansari S; Faraj H; Alateeg S; Akiki SJ; Yassin MA
    Hematology; 2024 Dec; 29(1):2360246. PubMed ID: 38804886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Wu Z; Zhang X; Xu X; Chen Y; Hu T; Kang Z; Li S; Wang H; Liu W; Ma X; Guan M
    J Hematol Oncol; 2014 Jul; 7():48. PubMed ID: 25023898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
    Alshemmari SH; Rajan R; Ameen R; Almazyad M
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):483-488. PubMed ID: 33858806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.
    Lin Y; Liu E; Sun Q; Ma J; Li Q; Cao Z; Wang J; Jia Y; Zhang H; Song Z; Ai X; Shi L; Feng X; Li C; Wang J; Ru K
    Am J Clin Pathol; 2015 Jul; 144(1):165-71. PubMed ID: 26071474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The spectrum of JAK2-positive myeloproliferative neoplasms.
    Kiladjian JJ
    Hematology Am Soc Hematol Educ Program; 2012; 2012():561-6. PubMed ID: 23233635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency.
    Hochman MJ; Smith BD; Karantanos T; Braunstein EM; Gojo I; Jain T; Streiff MB; Moliterno AR; DeZern AE
    Int J Hematol; 2023 Mar; 117(3):456-462. PubMed ID: 36181657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
    Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
    J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.